Study results in on metformin and lifestyle interventions for diabetes

Article

Study results show diabetes prevention is possible long-term with lifestyle intervention or metformin. The original 3-year Diabetes Prevention Program (DPP) study1 continued into a long-term follow up study called the Diabetes Prevention Program Outcomes Study (DPPOS), which examined patients with prediabetes and high risk for type 2 diabetes for 22 years, on average. Those patients who received either metformin or lifestyle intervention were less likely to develop diabetes than patients in the placebo group.

The first study, DPP, conducted in 1996-2001, revealed a 58 percent drop in diabetes incidence with lifestyle intervention and a 31 percent drop with metformin use, compared to the placebo group.

The follow-up study, DPPOS, revealed a 25 percent drop in diabetes incidence with lifestyle intervention and an 18 percent drop with metformin use, compared to the placebo group.

Related: Outlook Therapeutics updates status of Lytenava (bevacizumabvikg) NORSE 1

The study also found that participants who did not develop diabetes had significantly lower rates of eye (57 percent), kidney (37 percent), and major cardiovascular disease (39 percent), according to a statement.

"I think it is important for providers and patients with prediabetes to know that even after 22 years, adults at high risk for diabetes have continued to benefit from metformin or prior intensive lifestyle modification in preventing or delaying" diabetes,” says Christine Lee, MD, program director of the Division of Diabetes, Endocrinology, and Metabolic Diseases, at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in a statement.

Study results can be viewed at: https://www.clinicaltrials.gov/ct2/show/NCT00038727.

Related: CooperVision reveals virtual exhibit booth

Reference

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.

Recent Videos
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
© 2024 MJH Life Sciences

All rights reserved.